Clinical trials: MSK Conditions
Inflammation, Cataract
Study of Dexycu in Treating Intraocular Inflammation
This is a phase III, prospective, randomised, double-masked, placebo-controlled, parallel-design, multicenter study of the efficacy, safety and pharmacokinetics of 9% dexamethasone intraocular injection for the treatment of…
- Trial name
- NCT06429306
- Testing
- Dexycu
- Where
- China
- Volunteers
- 285 people
- Sponsor
- Ocumension Therapeutics (Shanghai) Co., Ltd
Age-related Macular Degeneration
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
This was a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with neovascular age related macular degeneration (nAMD) who have not previously received anti- vascular endothelial growth…
- Trial name
- TALON (NCT04005352)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 118 sites in United States, Argentina and 18 more
- Volunteers
- 734 people
- Sponsor
- Novartis Pharmaceuticals
Surgical Incision, Pain, Postoperative
Continuous Erector Spinae Plane Blocks to Treat Postoperative Pain After Open Gynecologic Procedures Via a Low Transverse (Pfannenstiel) Incision
Open gynecologic surgery can be very painful. With the goal of minimizing the use of opioids (with undesired side effects and potential for abuse), the investigators often administer a type of peripheral nerve block in which the…
- Conditions
- Surgical Incision, Pain, Postoperative, Pain, Acute
- Trial name
- NCT05082155
- Testing
- Bupivacaine 0.25%, Normal Saline
- Where
- United States
- Sponsor
- University of California, San Diego
Wet Age-related Macular Degeneration
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
This Phase 3 study will evaluate the efficacy and safety of KSI-301 compared to aflibercept, in participants with neovascular (wet) age-related macular degeneration (wAMD)
- Trial name
- DAYLIGHT (NCT04964089)
- Testing
- KSI-301, Aflibercept
- Where
- 66 sites in United States, Puerto Rico
- Volunteers
- 557 people
- Sponsor
- Kodiak Sciences Inc
Postoperative Pain
Oral Gabapentin Versus Placebo for Treatment of Postoperative Pain Following Photorefractive Keratectomy
The purpose of this study is to determine the effectiveness of an oral medication called gabapentin in reducing pain after Photorefractive Keratectomy (PRK) eye surgery and to assess the frequency of use of rescue medication…
- Trial name
- NCT00793910
- Testing
- Gabapentin
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Walter Reed Army Medical Center
Neuropathic Pain
The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain
The primary objective of this study, in subjects with Neuropathic Corneal Pain, is to evaluate the efficacy and safety of OK-101 0.05% and 0.1% as compared to placebo instilled 4 times/day in subjects with neuropathic corneal…
- Trial name
- NCT06637527
- Testing
- OK-101 0.05%, OK-101 0.1%
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Okyo Pharma Ltd
Age-related Macular Degeneration, Choroidal Neovascularization
Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD
This study was designed to evaluate the efficacy and safety of two different regimens of 0.5 mg ranibizumab given as intravitreal injection in patients with neovascular age-related macular degeneration
- Trial name
- TREND (NCT01948830)
- Testing
- Ranibizumab 0.5mg
- Where
- 91 sites in Belgium, Chile and 17 more
- Volunteers
- 650 people
- Sponsor
- Novartis Pharmaceuticals
Idiopathic Pulmonary Fibrosis
A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
The aims of the study are to assess safety, tolerability, the pharmacokinetic profile, and the pharmacodynamic profile of multiple doses of PRM-151 administered IV to IPF patients.
- Trial name
- PRM151F-12GL (NCT01254409)
- Testing
- PRM-151
- Where
- 3 sites in United States, Netherlands
- Volunteers
- 21 people
- Sponsor
- Hoffmann-La Roche
Inflammation, Pain
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation
The purpose of this study is to evaluate the clinical efficacy and safety of XG-102 (900µg) compared to vehicle in the treatment of subjects with inflammation and pain following cataract surgery.
- Conditions
- Inflammation, Pain, Cataract
- Trial name
- NCT02235272
- Testing
- XG-102
- Where
- United States
- Volunteers
- 339 people
- Sponsor
- Xigen SA
Inflammation Corneal, Pain, Postoperative
OCS-01 in Treating Inflammation and Pain in Post-cataract Patients
The DX-216 trial is a randomized, double-masked, placebo (vehicle)-controlled study evaluating the efficacy and safety of two doses of OCS-01 compared to vehicle in the treatment of inflammation and pain following cataract…
- Trial name
- SKYGGN (NCT04130802)
- Testing
- OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL
- Where
- 4 sites in United States
- Volunteers
- 153 people
- Sponsor
- Oculis
Infant, Newborn, Infant, Low Birth Weight
The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants
This study tested the safety and efficacy of transfusing erythropoietin (Epo) and iron in infants of <1,250g birth weight. For infants 401-1,000g birth weight, we tested whether early erythropoietin (Epo) and iron therapy would…
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
- Trial name
- EPO (NCT01203514)
- Testing
- Erythropoietin
- Where
- 9 sites in United States
- Volunteers
- 318 people, healthy volunteers welcome
- Sponsor
- NICHD Neonatal Research Network
Postoperative Pain
A Comparison of Pregabalin (Lyrica®) to Placebo in Pain Relief After Photorefractive Keratectomy (PRK) Surgery
The purpose of this study is to compare the efficacy of pregabalin to placebo for postoperative pain control after photorefractive keratectomy.
- Trial name
- NCT01097577
- Testing
- pregabalin
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- 59th Medical Wing
Chronic Hepatitis C
Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment
Silymarin (Legalon), also known as milk thistle, is an alternative medicine commonly found in health food and vitamin stores. People with liver disease sometimes use silymarin because it is thought to have liver protecting…
- Trial name
- SyNCH (NCT00680342)
- Testing
- Silymarin
- Where
- 5 sites in United States
- Volunteers
- 154 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Choroidal Neovascularization (CNV)
Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.
This study was conducted to evaluate the efficacy and safety of 0.5 mg ranibizumab in adult and adolescent patients with visual impairment due to choridal neovascularization (CNV).
- Trial name
- NCT01840410
- Testing
- Ranibizumab
- Where
- 59 sites in Australia, Canada and 19 more
- Volunteers
- 183 people
- Sponsor
- Novartis Pharmaceuticals
Ocular Inflammation and Pain
Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of ocular inflammation and pain in subjects who have undergone…
- Trial name
- NCT01666210
- Testing
- OTX-DP (Dexamethasone punctum plug)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Ocular Therapeutix, Inc.
Post Surgical Ocular Inflammation
A Study of TRS01 in Participants With Post-surgical Ocular Inflammation
The objective of this study is to evaluate the safety and preliminary efficacy of TRS01 eye drops as compared to placebo on participants with ocular inflammation after cataract surgery.
- Trial name
- NCT04222725
- Testing
- TRS01 eye drops
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- Tarsier Pharma
Choroidal Neovascularization, Diabetic Retinopathy
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
This is a two-part study. The first part (Stratum I) is an open-label, dose escalation, safety, tolerability and pharmacokinetic study, where active study drug (PF-04523655) will be given to all patients who participate.
- Conditions
- Choroidal Neovascularization, Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- MATISSE (NCT01445899)
- Testing
- PF-04523655 (Stratum I), ranibizumab, PF-04523655 (Stratum II)
- Where
- 51 sites in United States, Belgium and 5 more
- Volunteers
- 258 people
- Sponsor
- Quark Pharmaceuticals
Low Back Pain, Low Back Pain, Mechanical
Diaphragm Function in Low Back Pain People
Pathomechanism of nonspecific low back pain is not clear for the researchers yet. Our aim is to evaluate the function of one of the stabilizer muscles of the low back area. Diaphragm's postural function is evident.
- Trial name
- LBP_DIA (NCT05486858)
- Testing
- MSK ultrasonograpy, sitting Functional and Lateral Reach Test
- Where
- Hungary
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Szeged University
Blepharitis, Signs and Symptoms
Efficacy and Safety of Posiformin 2 % Eye Ointment in the Treatment of Blepharitis
This is a multicentre, randomised, double-masked, parallel-group, phase IV comparison of Posiformin 2 % eye ointment (active substance: bibrocathol) in the treatment of blepharitis.
- Trial name
- NCT01357538
- Testing
- Posiformin 2 %, bibrocathol
- Where
- Ukraine
- Volunteers
- 197 people
- Sponsor
- Ursapharm Arzneimittel GmbH
Diabetic Kidney Disease, Diabetic Nephropathy
A Study in Participants With Diabetic Kidney Disease
The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
- Trial name
- NCT01113801
- Testing
- LY2382770
- Where
- 78 sites in United States, Australia and 5 more
- Volunteers
- 417 people
- Sponsor
- Eli Lilly and Company